Dr. Rotow on the Implications of Next-Generation ALK Inhibitors in NSCLC
In Partnership With:
Julia Rotow, MD, discusses the implications of next-generation ALK inhibitors in non–small cell lung cancer.
Julia Rotow, MD, medical oncologist, Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, discusses the implications of next-generation ALK inhibitors in non—small cell lung cancer (NSCLC).
An increasing number of next-generation ALK inhibitors is emerging for the treatment of patients with ALK-positive NSCLC, says Rotow.
As such, upfront molecular testing with next-generation sequencing is critical to identify patients with an ALK alteration.
Additionally, patients with central nervous system (CNS) disease should be considered for treatment with next-generation agents such as alectinib (Alecensa) or brigatinib (Alunbrig) as they have demonstrated marked CNS activity, explains Rotow.
Starting a patient on systemic therapy may initially spare them the toxicities associated with radiation, while allowing them to achieve good disease control, concludes Rotow.
